The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.
The conversation is about making homemade topical finasteride, discussing mixing it with Kirkland minoxidil and creating a solvent with alcohol, glycerin, and water. A formula suggestion includes 50% ethyl alcohol, 25% propylene glycol, and 25% distilled water.
The user experiences histamine intolerance with alcohol-based hair loss treatments like Rogaine foam and seeks alternatives. Suggestions include alcohol-free and PPG-free topical minoxidil or finasteride, and trying Spectral products with different solvents.
The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.
The user is concerned about the toxicity of a homemade topical solution of minoxidil and finasteride to their new kitten and is considering replacing minoxidil with stemoxydine. Other users suggest using oral treatments, keeping the solution away from the cat, and ensuring proper hygiene.
A user discusses their experience with dissolving high concentrations of minoxidil in various ethanol/PG ratios and mentions difficulties with combining it with RU58841. They note that a 5% minoxidil solution remains stable, while higher concentrations tend to precipitate.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.
Mixing finasteride pills with stemoxydine is not recommended due to potential solubility and safety issues. It's advised to consult a healthcare provider for professionally formulated topical finasteride products.
Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.
Chlorine dioxide was discussed as a potential hair growth treatment, with a method involving spraying it on the scalp and covering it with a cap. Concerns were raised about its safety, comparing it to bleach.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.